


2<sup>ND</sup>

# HEALTH MEETS FUTURE SUMMIT

**PROGRAM**

June 18, 2018

Westhafen Pier 1, Frankfurt am Main, Germany



#HealthSummit

# DIGITAL ATTACK ON HEALTH AND CARE

by **Panagiotis Siskos**,  
Head of Content & Concepts, Convent GmbH

For decades Germany was considered to be the pharmacy of the world, and medical devices developed in this country enjoy a high reputation. We have to acknowledge that powerful tech giants from outside the sector are increasingly forcing their way into the health industry. The digital transformation has already reached our health.

The Health meets Future Summit, initiated in 2017, takes this increasing digitalization of the health sector into account and is dedicated to innovations in medicine, the pharmaceutical industry, life sciences and biotech.

Healthcare is currently one of the most prevalent and growing topics in the digital community. Digitization is fostering the monetization of data and the implementation of artificial intelligence and blockchain technology. Precision medicine and its data-driven approach to health care has a widespread impact on all areas, from genomics to medical devices. Innovation in the medical industry has the potential to profoundly affect each and everyone of us.

In the first session we will discuss, how we can develop digital business models in the healthcare sector and the data privacy issues we do have to keep in mind. The way patient care and

prevention can benefit from this, will be the focus of the second session. The digital attack and what we can expect from the future is on the agenda of the third session.

The Health meets Future Summit will highlight current findings from research and development as well as new digital business models and their growth potential. With selected masterminds and decision-makers, the summit will facilitate exchanges and information on the highest level, also thanks to the support of our partners.

I am looking forward to welcoming you to this year's Health meets Future Summit and wish you interesting discussions and stimulating talks!

## PROGRAM

9.30 AM **REGISTRATION AND WELCOME COFFEE**

10.30 AM **WELCOME ADDRESS**

**Moderator of the day:**  
**Julia Bauer**  
Journalist and Moderator



## BIG PICTURE

10.40 AM **ONE-ON-ONE**

### IMPROVING HEALTHCARE THROUGH MEANINGFUL USE OF DATA

**Arantxa Unda**  
Chief Executive Officer, Sigesa



**Moderator:**  
**Thomas Fischermann**  
Editor, ZEIT



## SESSION I

### BIG DATA, ARTIFICIAL INTELLIGENCE AND BLOCKCHAIN

The digitization is fostering the monetization of data and the implementation of artificial intelligence and blockchain technology. How can we develop digital business models in healthcare sector and which data privacy issues do we have to keep in mind?

11.10 AM **INTRODUCTORY STATEMENT**

**Moderator of Session I**  
**Martina Flammer, MD, MBA**  
Vice President, Clinical Development & Medical Affairs, Specialty Care, Boehringer Ingelheim



11.20 AM **IMPULSE**

**Start Your Digital Business Now!**  
How to offer new digital products and services.  
Why should the European pharmaceutical industry become more digital?  
Change your business step by step.

**Jens von der Brelie**  
Partner, Zühlke



**Jan Horvat**  
Senior Business Development Manager,  
Zühlke



11.45 AM **DISCUSSION**

### Utilization and Monetization of Healthcare Data

**Prof. Dr. Hans-Hermann Dirksen**  
Professor for Medicine- and Health Law,  
Hochschule Fresenius – University of Applied Sciences



**Dr. Dietmar Frey**  
Project Leader PREDICTioN 2020  
Predictive Modeling in Medicine, Charité University Medicine



**Jens von der Brelie**  
Partner, Zühlke



12.30 PM **LUNCH**

## THE NEXT BIG THING

1.30 PM

### KEYNOTE

#### LEADING EDGE OF CYBERNICS: FUSION OF HUMANS, ROBOTS AND INFORMATION SYSTEMS

Pioneering the Future "Society 5.0!"  
for Global Health

##### Dr. Yoshiyuki Sankai

President and CEO, CYBERDINE INC.,  
Professor Dr., University of Tsukuba,  
Program Manager, ImPACT, promoted by  
Cabinet Office, Government of Japan



**Robot Suit HAL**  
CYBERDINE INC.



## SESSION II

### THE EVOLUTION OF HEALTHCARE

Precision medicine and its individually tailored approach  
to health care has a widespread impact on everything  
from genomics to medical devices. What can we expect  
from the future? And how can individualized patient  
care and prevention become affordable?

2.00 PM

### INTRODUCTORY STATEMENT

**Moderator of Session II**  
**Thomas Fischermann**  
Editor, ZEIT



2.10 PM

### BEST PRACTICE

**Precision medicine:  
Not if but How!**

**Herna Muñoz-Galeano**  
Managing Director,  
HMG Systems Engineering



2.30 PM

### DISCUSSION

**Precision Medicine:  
Key to Advancing the Future of  
Healthcare**

**Dr. Armin Furtwängler**  
Global Senior Medical Director,  
Health Care Innovation,  
Boehringer Ingelheim



**Dr. Jutta Heix**  
International Advisor,  
Oslo Cancer Cluster



**Prof. Dr. Berthold Huppertz**  
Chair, Department of Cell Biology,  
Histology & Embryology, Gottfried  
Schatz Research Center, Medical  
University of Graz, Austria



**Prof. Dr. Hans Lehrach**  
Co-Founder of several Biotechnology  
Companies, Director, Max Planck  
Institute for Molecular Genetics



3.30 PM

### COFFEE BREAK

## SESSION III

### DIGITAL ATTACK: THE DISRUPTION OF THE HEALTHCARE SECTOR

Modern medicine has a constantly changing and growing lexicon: Artificial intelligence, big data, blockchain, data mining, machine learning, patient engagement and countless more terms are known as the common buzzwords. But what are the real innovative and disruptive topics in the digital health sector?

4.00 PM

#### INTRODUCTORY STATEMENT

##### Moderator of Session II

**Dr. Mark Lightowler**

Founder and CEO, Phorix Limited



4.15 PM

#### DISCUSSION

##### Dr. Boris Adryan

Expert for IoT & Data Analytics  
Chief Digital Office; Merck KGaA



##### Dušan Beblavý

CTO Medical technologies for Europe,  
GlobalLogic



##### Dr. Philipp Diesinger

Head of Global Data Science,  
Boehringer Ingelheim



##### Murat Vurucu

Co-Founder and CEO,  
Latentine



5.15 PM

#### CONCLUSION

##### Julia Bauer

Journalist and Moderator



5.30 PM

#### GET-TOGETHER

## PARTNER

Premium Partner:



Partner:



Supporter:



Networking Partner:



In cooperation with  
ZEIT publishing group:



Media Partner:



## SPEAKER



**DR. BORIS ADRYAN** is a molecular biologist by training, with about 50 peer-reviewed publications in the life sciences. From 2008 to 2016 he was a Royal Society research group leader for computational genomics at the University of Cambridge, where he also taught data science and machine learning in an interdisciplinary degree programme. From 2014 his interests shifted to technology and connected products. In the meantime, Dr. Adryan has become an internationally renowned expert for IoT and M2M, and he is the lead author of "The Technical Foundations of IoT" (Artech House, Boston/London). After a short stint as Head of IoT & Data Analytics at Zühlke Engineering GmbH, he is now acting as expert and consultant within the Chief Digital Office at chemical and pharmaceutical company Merck KGaA.



Whether in Europe, Brasil, China, India or Pakistan - when **JULIA BAUER** enters a stage or a screen, the audience is thrilled. Her profound business, political and automotive knowledge combined with an inexhaustible good mood and clear voice makes her the perfect TV and event presenter. Julia has studied at Munich Business School, the Diplomatic Academy in Vienna, Columbia University and London School of Economics. After an intensive training at Germany's leading private news television channel N24 in Berlin, she has now moved to Cologne to work in front of the cameras of state-owned WDR and auto motor and sports channel. She has hosted political panels as well as events, business talks, press conferences and galas for the German Federal Bank, Lufthansa, the German Design Award, Mercedes, Porsche, Volkswagen, Audi, Citroen, Federal Ministries, CANON and many more. Furthermore, Julia teaches communications at major German universities and offers media trainings for improved presentation skills to professional as well as managerial staff.



**DUŠAN BEBLAVÝ** is acting as CTO Medical technology for Europe at GlobalLogic and has more than 17 years of experience in software development with many successfully completed medical and also non-medical projects. Expertise in C/C++, iOS, ARM, AVR, Web services, DB SQL systems, Windows mobile, Symbian, QT, distributed and client-server applications development, strong skills in designing applications' architecture, technical researches and databases design. Innovative thinking out of the box, Dusan has been supporting several medical disruptive innovations around the globe. Experience in managing teams of developers. Personal projects experience with embedded systems and low level programming. Interested in firmware programming and reverse engineering. Ability to quickly switch between several ongoing independent projects. Ability to work and troubleshoot individually, team player, communicative, skilled at learning new concepts quickly, working well under pressure, manage high workload, helpful can-do attitude, responsible.



**JENS VON DER BRELIE** joined Zühlke in 2011 where he is working with customers and partners to design and deliver IoT solutions for Medtech and Pharma. He has a long track record, in the development and the application of automation, controls and IoT in various industries. He holds a Dipl.-Ing. degree in Electrical Engineering with a major in data technology from the Braunschweig University of Technology.



**DR. PHILIPP DIESINGER** is a passionate data scientist who firmly believes that data-driven scientific problem solving will significantly transform industries and economies on a large scale.

Dr. Diesinger started his career as a data scientist in 2009 as a researcher at the Massachusetts Institute of Technology following his PhD in theoretical physics. From 2012, he worked for different companies and startups and joined with SAP Global Data Science Consulting in 2014. At SAP, he developed smart data science solutions for globally operating customers and scaled the data science team's life science engagements. Dr. Diesinger joined with Boehringer Ingelheim in November 2015 as Global Head of Data Science and has since been leading and developing the company's data science capabilities following a quant-level approach driven by the philosophy that the impact of data science is maximized through bright minds and scaled through technology. The artificial intelligence solutions Dr. Diesinger and his team have been working on enabled Boehringer Ingelheim to adopt industry leading positions in key areas.



**PROF. DR. HANS-HERMANN DIRKSEN** is a lawyer at LIEBENSTEIN LAW - law firm for commercial law in Frankfurt am Main. He studied law in Kiel and then did his doctorate in Greifswald summa cum laude. Prof. Dirksen specializes in the law of digitization and Industry 4.0 and advises on the drafting and incorporation of intellectual property and new technologies. His special emphasis is placed on the creation and negotiation of license- and IT-project-contracts as well as in data protection and healthcare law. Prof. Dr. Dirksen regularly speaks and publishes on current issues of IT-law, IT-security and Blockchain technology. Since 2015, he has been professor at the Hochschule Fresenius Frankfurt.



**THOMAS FISCHERMANN** is an editor at Die ZEIT, covering issues of economic globalization, technological innovation and their effects on society and business. His last major piece on health sector innovation appeared in May 2018 and was titled „The Doctor in My Pocket“ (<https://www.zeit.de/2018/20/digitale-medizin-fernbehandlung-aerzte-technischer-fortschritt>). After studying economics and political science in Cologne and Sussex, he became a financial market correspondent in London. From 2001, he headed the New York bureau of Die ZEIT, moved to Hamburg in 2006 to coordinate the reporting on international economic issues, and then became bureau chief for Die ZEIT in South America in 2013. Since 2018, he lives half in Hamburg and half in Rio de Janeiro.



**DR. MARTINA FLAMMER** operates at the forefront of functional developments in Market Access, Pricing & HEOR, Epidemiology and Real World Evidence (RWE) to advance state-of-the-art standards and ensure they are consistently applied and met throughout the organization from drug development, via product launches to lifecycle management. Together with her leadership team, Martina integrates novel data-scientific methods to drive efficiencies in medical and commercial data generation, data synthesis and data utilization across BI that provides medical and/or commercial value to customers.

In-depth functional and customer knowledge informs functional market shaping. It also enables to champion new business models and value-adding collaborative partnership concepts with payers, organized providers and patient advocacy groups, across and beyond selling product. Prior to this role, Dr. Flammer was the Vice President, Clinical Development & Medical Affairs for Specialty Care in Ridgefield, where she had responsibility for oncology, immunology, interstitial lung diseases, CNS and the biosimilar therapeutic area. Dr. Flammer joined Boehringer Ingelheim

6 years ago and after 2 years in a global medical leadership role, gained operational experience as Medical Director for BI in Canada where she oversaw all aspects of the company's, development & medical, clinical operations, regulatory affairs, drug safety and clinical quality management. Prior to joining BI, Dr. Flammer worked at Pfizer's New York headquarters for 11 years where she held various leadership roles in global medical and commercial settings. Martina launched 3 medicines in Pfizer's key drug franchises and after completing her MBA, she transitioned to a commercial role in market access and evaluation of business models in emerging markets. She received 3 distinguished leadership awards, a Pharmaceutical Executive Best Brand Award and with her team a Prix Gallien for best new molecule. Dr. Flammer received her MD degree from the University of Vienna, Austria and her training in Internal and Emergency Medicine in Austria and the US. She obtained her MBA from the Stern School of Business at New York University with specializations in finance, leadership and global business.



**DR. DIETMAR FREY** is a neurosurgeon by training and injects entrepreneurial spirit into research. After obtaining a law degree and passing the bar examination in Berlin in 2003 Dietmar went to Charité Medical School. In 2007, he graduated and specialized in the Charité Department of Neurosurgery. He is a certified board member in neurosurgery since 2013. For the last 4 years, he has been working on advancing stroke treatment by personalized imaging-based stroke prediction. Funded by several federal grants he has built a strong interdisciplinary team of physicians, software engineers and computer scientists to develop AI decision support that provides risk scoring and treatment planning in stroke. He is currently heading the research group Predictive Modeling in Medicine in the Charité. He leads PRECISE4Q, a joint venture of 11 partners in Europe to create data-driven support systems for medicine. It is funded via the Horizon 2020 framework with €5.9m.



**DR. ARMIN FURTWÄNGLER** originally trained as a physician is board-certified in internal medicine, cardiology and interventional cardiology, as well as emergency medicine. Since 2001 Armin is working in clinical development and medical affairs roles in the pharmaceutical industry. Since July 2016 Armin is acting as Global Senior Medical Director in Health Care Innovation within the Boehringer Ingelheim Group of Companies, with responsibilities covering all therapeutic areas within Boehringer Ingelheim, as an „Intrapreneuer“ and „Disruptive Innovator“.



**DR. JUTTA HEIX** is a life science professional with more than 20 years of industry experience. She holds a PhD in molecular biology from the University of Heidelberg /German Cancer Research Center and has worked in different Business Development roles in international pharma and biotech companies prior to joining Oslo Cancer Cluster. Her current responsibilities and initiatives include: Business Development interface for Oslo Cancer Cluster's members, pipeline and partnering opportunities towards international partners from industry, academia and the investment community. Planning and execution of national and international meetings, partnering events and conference sessions. Facilitation / Organization of innovation projects in Precision Medicine and Immuno-Oncology. Consortium partner in Horizon2020 Project PERMIDES (Personalized Medicine Innovation through Digital Enterprise Solutions) - a cross-sectoral cluster collaboration initiating and funding novel collaboration projects between biopharma and IT SMEs. Co-Founder of the Norwegian SPARK Academic Innovation Program in Oslo and member of Management Team (SPARK Norway is based on Stanford University's SPARK Program and part of the SPARK Global Network).





Joining Zühlke in 2016 **JAN HORVAT** is acting as Senior Business Development Manager for Digital Business Innovation (New Digital Business Models, IoT, Industry 4.0, AI, Blockchain) focused on the Pharmaceutical Industry. He has a long track record in several strategic and operational management positions leading international product and software development alliances in various tech-industries (pharmaceutical, machinery, aerospace, automotive). He holds a Dipl. Wirtschaftsingenieur (FH) degree in Industrial Engineering and Management studying at University of Technology Mittelhessen and Universidad Politécnica de Madrid.



**PROF. DR. BERTHOLD HUPPERTZ** is PhD and professor of cell biology. From 2011 to 2017 he has been director and CEO of Biobank Graz, the largest clinical biobank in Europe with more than 20 million samples. Biobank Graz is a publicly owned and certified (ISO 9001) organization located at Medical University of Graz (Austria), which focuses on offering specialized scientific services, infrastructure, and technologies to foster personalized medicine and therapies. Biobank Graz was awarded "Research Biobank of the Year" in 2014, "Best European Academic Biobank" in 2016 and "Most Outstanding Academic Biobank" in 2016. Berthold has moved Biobank Graz towards automation to maintain highest sample quality and has installed the first e-learning, part-time course "Master in Biobanking" in English. For more than 20 years Berthold has worked in reproductive biology and medicine, developing new concepts of disease development and validating new biomarkers for the prediction of pregnancy pathologies. He has published over 200 papers in peer-reviewed scientific journals, works in the editorial boards of a number of journals and has been member of the executive committee of IFPA, the International Federation of Placenta Associations. Berthold belongs to the most cited German speaking scientists in the field of reproductive biology.



**PROF. DR. HANS LEHRACH** originally studied chemistry in Vienna and received his Ph.D. in Biophysics for work at the Max Planck Institute for Biophysical Chemistry. After a Postdoc in Harvard he led a research group at the EMBL, moved to the ICRF to head a department for genome analysis, and then to the Max Planck Institute for Molecular Genetics as Director. In his work he has pioneered new approaches in molecular biology, positional cloning, genome research and functional genomics, and, most recently systems biology and systems medicine. He has founded a number of companies, and coordinates Digital Twins for Better Health, a FET-Flagship proposal, which has just reached the second stage of a CSA call.



**DR. MARK LIGHTOWLER** originally trained as a medicinal chemist in England and has a Ph.D. and post-Doctoral experience from Bath University. During the last twenty years he has worked across many roles from drug discovery, clinical development, sales and marketing. As global head of digital solutions for respiratory at Novartis he was focused on digital healthcare innovation, where technology meets health outcomes. Two years ago he started Phorix Limited, a Basel and London based company focusing on catalyzing innovation and harnessing the power of Patient-Led design to improve healthcare interventions. Separately he writes on the science and art of storytelling and how to make science memorable.



**HERNA MUÑOZ-GALEANO** has over 25 years of experience in specification, development, integration and management of complex engineering systems. Since 1998, Herna has been an independent entrepreneur with a special interest in transforming science into innovative products and systems. She also has knowledge of standardization at ITU, ETSI and IEEE. She has perfected the methods which optimize the development process, including integration and testing processes,

for breakthrough complex technical systems. By applying the “functional anatomy” method, all projects have been completed within the given time frame and budget. Herna’s way of working is analytic and systematic and has made her who she is today. Respect, openness and trust are very important to her. Her employees and customers value her fast and logical judgment as well as her reliability and social competence. She is client-service oriented and is always open for new challenges. Due to her international background, Herna Muñoz-Galeano speaks English and German fluently and Spanish is her native language. She has implemented projects in Germany, Sweden, Spain, the Netherlands, the United Kingdom and Brazil. Herna Muñoz-Galeano holds a master’s degree in Electronics Engineering from the Universidad Distrital Francisco José de Caldas in Bogotá, Colombia, and a master’s degree in Computer Science from the Friedrich-Alexander-University in Erlangen-Nuernberg, Germany. On 29th April 2016, Herna Muñoz-Galeano was awarded the Career Award “Engineer PowerWoman 2016” by the Deutsche Messe AG at the Hannover Messe. Since 1998, Herna has been an independent entrepreneur and managing director of HMG Systems Engineering GmbH, which emerged in 2014 from the merger of two other companies established by Herna. HMG Systems Engineering GmbH was awarded in 2016 as one of the Top 100 (top100.de) most innovative SMEs in Germany.



**ARANTXA UNDA** is the CEO of Sigesa, a Madrid-based developer of analytics solutions for hospitals and healthcare providers, helping more than 400 hospitals in several countries transform raw health data into actionable insights. Prior to joining Sigesa in 2013, Arantxa worked as investment banking analyst in the UK. Arantxa holds an MBA from the Harvard Business School (2015) and a Bachelor of Science Degree in International Business from Universidad Pontificia Comillas-ICADE and Northeastern University (2009). Arantxa Unda was named to Forbes 30 under 30 Europe 2017 list, as standout of the Science and Healthcare lists, and to Mujeres&Cia’s ‘100 Most Influential Women in Spain’ 2017 list.



**DR. YOSHIYUKI SANKAI** is a professor and Executive Research Director at the Center for Cybernetics Research, University of Tsukuba; the President and CEO of CYBERDYNE, INC.; and a Program Manager of the Impulsing Paradigm Change through Disruptive Technologies (“ImPACT”) program, which was initiated by the Council for Science, Technology and Innovation (“CSTI”) of the Cabinet Office in Japan. He is a fellow of the Robotics Society of Japan (“RSJ”) and the Society of Instrument and Control Engineers (“SICE”). He also served as Chairman and an Executive Board Member of Advanced Robotics. He is a member of Global Future Council on Human Enhancement of the World Economic Forum. He has received numerous awards, including: The 2005 World Technology Award (World Technology Network), The 2012 Capek Award (INNOROBO), The 2014 Technology Pioneer (World Economic Forum), Gold Prize of 2014 Edison Awards, DealWatch Awards 2013 IPO of the Year (Thomson Reuters), DealWatch Awards 2014 Innovative Equity Deal of the Year (Thomson Reuters), The 2016 DIA Japan Outstanding Contribution to Health Award, the 7th Robot Award (Ministry of Health, Labour and Welfare award), and the Prime Minister’s Award (the third Nippon Venture Awards) in 2017.



**MURAT VURUCU** is Co-Founder and CEO of Latentine. Latentine helps you to scale knowledge across your organisation and use it to reduce costs, gain revenues and innovate. Murat has experiences as a strategy consultant focused on digital solutions and re-organizations. He has led diverse technical teams in product development and is a guest lecturer at ESCP Europe for data science, machine learning and cybersecurity. He sold his previous business and co-launched Latentine to tackle the toughest scientific challenges in data. He studied industrial engineering and automation in Germany, Turkey and China and graduated with a Dipl. and M.Sc. in Management from ESCP Europe.





**Convent Gesellschaft für Kongresse und  
Veranstaltungsmanagement mbH**

A company of ZEIT publishing group

Senckenberganlage 10-12

60325 Frankfurt am Main/Germany

Telefon: +49 69 79 40 95 - 25

Telefax: +49 69 79 40 95 - 44

[www.convent.de](http://www.convent.de)

**FOLLOW US ON:**



[www.twitter.com/conventkongress](https://www.twitter.com/conventkongress)



[www.facebook.de/conventkongresse](https://www.facebook.de/conventkongresse)



[www.xing.com/companies/conventkongressegmbh](https://www.xing.com/companies/conventkongressegmbh)

